Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2017-10-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2017年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 Third Quarter Report" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data and analysis for the third quarter of 2017, including income, net profit, assets, shareholder information, and explanations of financial changes. The presence of comprehensive financial statements and substantive financial data for a period shorter than a full fiscal year clearly indicates this is an Interim / Quarterly Report. The document length is 7750 characters, which is sufficient to be a full report rather than a brief announcement. There is no indication that this is merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2017
2017-10-26 Chinese
独立董事关于对北京崇德英盛创业投资有限公司增加1550万元投资额的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion on an increase in investment amount by the company. It references compliance with company law, stock exchange listing rules, and company articles, and it is a formal statement approving an investment decision. The content is related to a capital investment update rather than a full financial report, earnings release, or management discussion. The document length is short (555 characters), and it is a formal opinion on a financing decision, which fits best under Capital/Financing Update (CAP).
2017-10-26 Chinese
关于公司部分董事、高级管理人员减持计划的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding a planned reduction of shares held by certain directors and senior management of the company. It details the number of shares to be sold, the reasons for the sale, the source of shares, the timing, and the method of sale. It references regulatory provisions related to share reduction by insiders. The document is an announcement of insider share transactions (directors and senior management selling their shares), not a full report or financial statement. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on this insider share reduction plan, confirming it is not a full financial report or other type of filing.
2017-10-26 Chinese
2017年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2017 年第三季度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2017 Third Quarter Report Full Text." It contains detailed financial data including balance sheets, profit and loss statements, cash flow information, and management commentary for the third quarter of 2017. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-10-26 Chinese
第六届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing SL Pharmaceutical Co., Ltd. It details the decisions made at the 12th meeting of the 6th board, including approval of the company's 2017 Q3 report and an investment increase in a venture capital company. The document includes no actual financial statements or detailed financial data but references the 2017 Q3 report as published elsewhere. The document primarily announces board decisions and investment updates, not the full quarterly report itself. Given the content and length (1969 characters), this is not a full Interim/Quarterly Report but rather a Board/Management Information announcement about board resolutions and investment decisions.
2017-10-26 Chinese
独立董事对公司第六届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several company matters including related party transactions, equity transfer, and accounting policy changes. It references compliance with regulatory guidelines and company bylaws but does not contain financial statements or detailed financial data. The document is a formal opinion or statement related to board matters rather than a full report or announcement of financial results. It is not an Annual Report, Interim Report, or Earnings Release. It is also not a simple announcement or certification. The content aligns best with Board/Management Information (MANG) as it involves independent directors' opinions on board meeting matters and company governance issues.
2017-08-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.